'New Kids on the Block' in Chronic Kidney Disease

Authors

Chao-Yu Hsu, Rochester Regional HealthFollow
Ana Molovic-Kokovic, Rochester Regional HealthFollow
Stephen Silver, Rochester Regional HealthFollow
Marvin Grieff, Rochester Regional HealthFollow

Document Type

Presentation

Department

Nephrology

Abstract

Sodium-Glucose Cotransporter 2 Inhibitors: Role in Renal Disease, Dr. Chao-Yu Hsu. Overview:

• History
• Mechanism of Action
• Use in diabetic kidney disease
• Beyond diabetic kidney disease
• Considerations and limitations

GLP-1 Receptors Agonists use in Diabetic Kidney Disease, Dr. Ana Molovic-Kokovic

Finerenone: A Third Generation Mineralocorticoid Receptor Antagonist, Dr. Steve Silver

To Recap, Dr. Marvin Grieff

• SGLT2 inhibitors
• GLP-1 agonists
• Finerenone

Publication Date

3-3-2022

Comments

00:02:27 Sodium-Glucose Cotransporter 2 Inhibitors: Role in Renal Disease

00:17:12 GLP-1 Receptors Agonists use in Diabetic Kidney Disease

00:38:05 Finerenone: A Third Generation Mineralocorticoid Receptor Antagonist

00:54:10 To Recap

Recommended Citation

Hsu, C., Molovic-Kokovic, A., Silver, S., & Grieff, M. (2022). 'New Kids on the Block' in Chronic Kidney Disease. Retrieved from https://scholar.rochesterregional.org/grandrounds_rgh/14